Hybrigenics
Paris
About Hybrigenics
Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $70.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2017)
- Ticker: epa:ALHYG
- Website: hybrigenics.com
- Phone: +33 (0) 158103800
Industries & Categories
Bioinformatics, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hybrigenics-2226017 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.